Barely Significant
← all excerpts

SOX plus sintilimab <i>vs</i> P-SOX <i>vs</i> SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety.

World J Gastrointest Oncol · 2025 · PMC12362546 · PMID 40837776

Europe PMCDOI
2
hedged sentences
—
closest p
—
boldest claim

The sentences

did not reach statistical significanceno p-value reported
Although these differences did not reach statistical significance, the SOX plus sintilimab regimen demonstrated a numerically superior ORR.

also in 111,027 other papers

showed a trendno p-value reported
In the postoperative adjuvant setting following D2 resection, P-SOX showed a trend toward improved 3-year disease-free survival (approximately 78.2% vs 74.0% after matching), along with a reduced risk of peritoneal metastasis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.